(Q43934617)

28 November 2017

title

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease (English)

1 reference

28 November 2017

1 reference

0 references

Olaf Stüve

1 reference

28 November 2017

Sawsan Youssef

1 reference

28 November 2017

Juan C Patarroyo

1 reference

28 November 2017

Pedro J Ruiz

1 reference

28 November 2017

Jennifer L Radosevich

1 reference

28 November 2017

Eun Mi Hur

1 reference

28 November 2017

Manuel Bravo

1 reference

28 November 2017

Dennis J Mitchell

1 reference

28 November 2017

Raymond A Sobel

1 reference

28 November 2017

Lawrence Steinman

1 reference

28 November 2017

Scott S Zamvil

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

28 November 2017

1 reference

28 November 2017

volume

420

1 reference

28 November 2017

issue

6911

1 reference

28 November 2017

page(s)

78-84

1 reference

Effect of pravastatin on outcomes after cardiac transplantation.

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

The T lymphocyte in experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

Inhibition of monocyte chemotactic protein-1 synthesis by statins

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

Statins as a newly recognized type of immunomodulator

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

Regulation of MHC class II genes: lessons from a disease

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

Contemporary immunomodulatory therapy for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

Cerivastatin and reports of fatal rhabdomyolysis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

Safety of HMG-CoA reductase inhibitors: focus on atorvastatin

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

Fertility and general reproduction studies in rats with the HMG-CoA reductase inhibitor, atorvastatin

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

T cells with two functional antigen-specific receptors

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

Selective abrogation of major histocompatibility complex class II expression on extrahematopoietic cells in mice lacking promoter IV of the class II transactivator gene.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

STATs and gene regulation

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

Regulation of the mevalonate pathway

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

Multiple sclerosis: a two-stage disease

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

Mouse microglial cell lines differing in constitutive and interferon-gamma-inducible antigen-presenting activities for naive and memory CD4+ and CD8+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FNATURE01158

7 January 2021

Identifiers

DOI

10.1038/NATURE01158

1 reference

Dimensions Publication ID

28 November 2017

1001566151

0 references

1 reference